Prime Medicine, Inc.
NASDAQ:PRMEBiotechnology
Healthcare
$3.84 -1.11%
-$0.04 today
- Market cap
- $698.58M
- Beta
- 2.31
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.12
52W Low $1.77High $6.94
Volume 3.99M
Average 2.47M
Balance Sheet
Inspect the capital base behind the business.
Assets
$342.73M
FY 2025 · Annual
+15.2% YoYLiabilities
$221.87M
FY 2025 · Annual
+53.7% YoYEquity
$120.87M
FY 2025 · Annual
-21.1% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 185.42M | 187.62M | 41.57M | 182.48M | 63.03M |
| Short-term Investments | 84.2M | 106.3M | 80.09M | 7.97M | 114.65M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 246K | 2.25M | 14.67M | 3.61M |
| Total Current Assets | 270.58M | 296.62M | 142.98M | 211.89M | 181.29M |
| Property, Plant & Equipment (Net) | 15.68M | 48.55M | 36.6M | 71.56M | 146.75M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 15.6M | 15.14M | 14.28M | 14.06M | 14.69M |
| Total Non-current Assets | 31.28M | 63.7M | 50.88M | 85.62M | 161.44M |
| Total Assets | 301.86M | 360.31M | 193.85M | 297.51M | 342.73M |
| Account Payables | 1.44M | 4.33M | 19.54M | 11.35M | 8.89M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 7.09M | 7.82M |
| Other Current Liabilities | 14.66M | 6.98M | 10.91M | 6.93M | 9.04M |
| Total Current Liabilities | 57.98M | 26.71M | 56.42M | 37.96M | 37.45M |
| Long-term Debt | 0 | 0 | 0 | 0 | 108.29M |
| Deferred Tax Liabilities | 1.24M | 279K | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 63.22M | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 6M | 76.13M |
| Total Non-current Liabilities | 4.31M | 17.33M | 4.36M | 106.4M | 184.42M |
| Total Liabilities | 62.3M | 44.04M | 60.78M | 144.36M | 221.87M |
| Common Stock | 1K | 2K | 2K | 2K | 2K |
| Retained Earnings | (171.38M) | (293.2M) | (491.33M) | (687.21M) | (888.35M) |
| Accumulated OCI | (27K) | (384K) | (15K) | 1K | 82K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 239.56M | 316.27M | 133.07M | 153.15M | 120.87M |
| Total Debt | 10.41M | 28.75M | 13.63M | 40.79M | 116.43M |
| Net Debt | (175.01M) | (158.88M) | (27.94M) | (141.68M) | 53.4M |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $64.1M |
| Short-term Investments | $71.4M |
| Other Current | $2.4M |
| Total Current Assets | $137.9M |
| PP&E (Net) | $142.2M |
| Other Non-current | $14.7M |
| Total Non-current Assets | $156.8M |
| Total Assets | $294.7M |
Analysis
Selected assets total $294.7M for Latest. The largest visible component is PP&E (Net) at $142.2M, about 48.2% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 |
How much cash does PRME have?
Prime Medicine, Inc. (PRME) reported $63.03M in cash and equivalents in fiscal 2025.
How much debt does PRME carry?
Prime Medicine, Inc. (PRME) reported $116.43M of total debt, with net debt of $53.40M.
Continue the stock analysis
Jump to another research area for this company.